JD HEALTH
06618
TRIP.COM-S
09961
NTES-S
09999
ALI HEALTH
00241
MEITUAN-W
03690
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | ---- | 1.11%558.62M | ---- | -31.54%552.51M | ---- | 160.46%807.04M | ---- | -4.38%309.86M | ---- | 0.05%324.04M |
Profit adjustment | ||||||||||
Interest (income) - adjustment | ---- | -98.45%-10.88M | ---- | -1,992.37%-5.48M | ---- | 80.40%-262K | ---- | 75.88%-1.34M | ---- | 37.27%-5.54M |
Impairment and provisions: | ---- | 11.70%32.25M | ---- | -17.13%28.88M | ---- | 45.26%34.84M | ---- | 499.23%23.99M | ---- | -61.75%4M |
-Impairment of property, plant and equipment (reversal) | ---- | ---- | ---- | --5.68M | ---- | ---- | ---- | ---- | ---- | ---- |
-Impairmen of inventory (reversal) | ---- | ---- | ---- | ---- | ---- | --2.12M | ---- | ---- | ---- | ---- |
-Impairment of trade receivables (reversal) | ---- | 6,231.45%7.6M | ---- | ---124K | ---- | ---- | ---- | ---- | ---- | ---- |
-Other impairments and provisions | ---- | 5.69%24.65M | ---- | -28.73%23.32M | ---- | 36.42%32.72M | ---- | 499.23%23.99M | ---- | -61.75%4M |
Revaluation surplus: | ---- | 142.61%8.77M | ---- | -617.08%-20.59M | ---- | -90.49%3.98M | ---- | 889.18%41.87M | ---- | --4.23M |
-Other fair value changes | ---- | 142.61%8.77M | ---- | -617.08%-20.59M | ---- | -90.49%3.98M | ---- | 889.18%41.87M | ---- | --4.23M |
Asset sale loss (gain): | ---- | -72.20%67K | ---- | -96.43%241K | ---- | 1,553.19%6.75M | ---- | 36.00%408K | ---- | -66.33%300K |
-Loss (gain) on sale of property, machinery and equipment | ---- | -72.20%67K | ---- | -96.43%241K | ---- | 1,553.19%6.75M | ---- | 36.00%408K | ---- | -66.33%300K |
Depreciation and amortization: | ---- | -10.99%211.22M | ---- | 13.07%237.3M | ---- | 35.96%209.86M | ---- | 40.01%154.36M | ---- | 0.52%110.25M |
-Amortization of intangible assets | ---- | 3.40%14.56M | ---- | 135.89%14.09M | ---- | 4,165.00%5.97M | ---- | -84.14%140K | ---- | --883K |
Financial expense | ---- | -3.31%32.8M | ---- | -9.10%33.92M | ---- | 0.79%37.32M | ---- | 122.27%37.02M | ---- | -32.24%16.66M |
Exchange Loss (gain) | ---- | -35.53%1.06M | ---- | 183.00%1.64M | ---- | -135.53%-1.98M | ---- | 333.00%5.56M | ---- | 394.23%1.29M |
Special items | ---- | 118.58%7.27M | ---- | 238.34%3.33M | ---- | -45.05%-2.41M | ---- | -365.73%-1.66M | ---- | 95.36%-356K |
Operating profit before the change of operating capital | ---- | 1.13%841.18M | ---- | -24.05%831.74M | ---- | 92.11%1.1B | ---- | 25.33%570.07M | ---- | 0.36%454.86M |
Change of operating capital | ||||||||||
Inventory (increase) decrease | ---- | -185.13%-35.2M | ---- | 123.10%41.35M | ---- | -26.65%-178.99M | ---- | -1,495.75%-141.33M | ---- | 106.46%10.13M |
Accounts receivable (increase)decrease | ---- | 72.02%-14.55M | ---- | 78.98%-51.99M | ---- | -349.22%-247.34M | ---- | 254.29%99.25M | ---- | -980.93%-64.33M |
Accounts payable increase (decrease) | ---- | -105.89%-7.41M | ---- | 4,889.21%125.83M | ---- | -92.10%2.52M | ---- | 48.49%31.92M | ---- | 497.38%21.5M |
Special items for working capital changes | ---- | 115.18%1.11M | ---- | -253.62%-7.33M | ---- | 71.85%-2.07M | ---- | -167.19%-7.36M | ---- | 182.05%10.96M |
Cash from business operations | ---- | -16.44%785.14M | ---- | 40.40%939.61M | ---- | 21.12%669.25M | ---- | 27.57%552.55M | ---- | 59.31%433.12M |
Other taxs | ---- | -24.68%-195.86M | ---- | -18.22%-157.09M | ---- | -89.57%-132.87M | ---- | -8.87%-70.09M | ---- | 2.67%-64.38M |
Special items of business | -10.95%413.12M | ---- | 67.56%463.92M | ---- | -25.10%276.86M | ---- | 430.55%369.66M | ---- | -57.26%69.68M | ---- |
Net cash from operations | -10.95%413.12M | -24.70%589.28M | 67.56%463.92M | 45.89%782.52M | -25.10%276.86M | 11.18%536.38M | 430.55%369.66M | 30.84%482.45M | -57.26%69.68M | 79.23%368.74M |
Cash flow from investment activities | ||||||||||
Interest received - investment | 178.55%8.74M | 98.45%10.88M | 1,469.00%3.14M | 1,992.37%5.48M | -53.05%200K | -80.40%262K | -44.82%426K | -75.88%1.34M | -74.96%772K | -37.27%5.54M |
Restricted cash (increase) decrease | 135.82%571K | 41.91%-607K | -217.53%-1.59M | -9.20%-1.05M | -197.86%-502K | -126.23%-957K | 143.40%513K | 185.75%3.65M | -273.06%-1.18M | 189.55%1.28M |
Loan receivable (increase) decrease | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -73.53%63K | -83.23%28K | -75.41%238K |
Decrease in deposits (increase) | 211.11%100M | -166.67%-80M | ---90M | ---30M | ---- | ---- | ---- | ---- | ---- | ---- |
Sale of fixed assets | --1.07M | --2.63M | ---- | ---- | ---- | 33.39%803K | ---- | 1,014.81%602K | ---- | -47.06%54K |
Purchase of fixed assets | 0.87%-83.62M | -213.15%-157.02M | -507.42%-84.35M | 75.48%-50.14M | 83.43%-13.89M | -43.59%-204.5M | -25.52%-83.83M | 65.11%-142.42M | 59.94%-66.79M | -14.61%-408.14M |
Purchase of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -266.77%-75M | ---- | ---20.45M |
Other items in the investment business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 3.08%1.44M | -81.82%2K | 1,920.29%1.39M |
Net cash from investment operations | 115.49%26.77M | -196.04%-224.12M | -1,117.90%-172.81M | 62.96%-75.71M | 82.88%-14.19M | 2.82%-204.39M | -23.42%-82.89M | 49.93%-210.33M | 66.37%-67.17M | -38.85%-420.08M |
Net cash before financing | 51.11%439.88M | -48.34%365.16M | 10.83%291.11M | 112.90%706.82M | -8.40%262.67M | 22.00%331.99M | 11,325.02%286.77M | 630.00%272.12M | 106.84%2.51M | 46.97%-51.34M |
Cash flow from financing activities | ||||||||||
New borrowing | 0.00%50M | -80.00%50M | -58.33%50M | -52.83%250M | -71.83%120M | 135.56%530M | 89.33%426M | -57.60%225M | -25.00%225M | 258.61%530.64M |
Refund | 31.28%-67M | 32.42%-401.5M | 35.00%-97.5M | 17.35%-594.13M | 67.43%-150M | -100.12%-718.85M | -610.59%-460.49M | 9.60%-359.21M | 50.54%-64.8M | -12.17%-397.34M |
Issuing shares | --124.08M | ---- | ---- | ---- | ---- | --126.89M | --126.89M | ---- | ---- | ---- |
Interest paid - financing | 67.89%-5.4M | 1.26%-31.12M | -25.28%-16.82M | 8.92%-31.52M | 23.46%-13.42M | 32.78%-34.6M | 39.60%-17.54M | 16.90%-51.48M | -3.11%-29.04M | -5.34%-61.95M |
Dividends paid - financing | 87.36%-6.65M | -9.11%-214M | -263.50%-52.63M | -61.37%-196.13M | 1.66%-14.48M | -109.17%-121.54M | 53.99%-14.72M | -36.39%-58.11M | -146.59%-32M | -66.34%-42.6M |
Net cash from financing operations | 178.78%94.86M | -4.43%-604.66M | -96.54%-120.41M | -157.28%-579M | -208.20%-61.26M | 9.96%-225.05M | -41.26%56.62M | -969.42%-249.94M | -22.80%96.39M | 111.37%28.75M |
Effect of rate | 170.31%682K | 35.53%-1.06M | ---970K | -183.00%-1.64M | ---- | 135.53%1.98M | 97.90%-18K | -333.00%-5.56M | -65.57%-856K | -394.23%-1.29M |
Net Cash | 213.26%534.74M | -287.38%-239.5M | -15.25%170.7M | 19.52%127.82M | -41.35%201.41M | 382.08%106.94M | 247.21%343.39M | 198.17%22.18M | 12.18%98.9M | 93.54%-22.6M |
Begining period cash | -32.82%492.36M | 20.80%732.92M | 20.80%732.92M | 21.88%606.75M | 21.88%606.75M | 3.45%497.83M | 3.45%497.83M | -4.73%481.21M | -4.73%481.21M | -40.92%505.09M |
Cash at the end | 13.86%1.03B | -32.82%492.36M | 11.69%902.65M | 20.80%732.92M | -3.93%808.15M | 21.88%606.75M | 45.22%841.2M | 3.45%497.83M | -2.27%579.25M | -4.73%481.21M |
Cash balance analysis | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | KPMG | -- | Ernst & Young | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.